This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
AMAG Posts Wider-Than-Expected Q3 Loss, Beats on Revenues
by Zacks Equity Research
AMAG reports wider than expected loss in the third quarter of 2018. The company completed the sale of Cord Blood Registry in August 2018.
Exelixis (EXEL) Q3 Earnings, Revenues Beat on Cabometyx Sales
by Zacks Equity Research
Exelixis's (EXEL) earnings and revenue beat expectations in the third-quarter propelled by strong sales of Cabometyx.
Novo Nordisk (NVO) Reports In-Line Q3 Earnings, Beats Sales
by Zacks Equity Research
Novo Nordisk (NVO) reports in line earnings in the third quarter of 2018 and announces restructuring plans.
Zoetis (ZTS) Beats on Q3 Earnings & Sales, Updates '18 View
by Zacks Equity Research
Zoetis (ZTS) beats both earnings and sales estimates in the third quarter of 2018. The company also updates its 2018 outlook.
5 Beaten Down Stocks of Spooky October With Upside Potential
by Sweta Killa
We have highlighted five stocks from the S&P 500 Index that were hit badly by market turmoil last month but might reverse the trend given encouraging fundamentals.
Clovis (CLVS) Q3 Earnings & Sales Lag, Rubraca Disappoints
by Zacks Equity Research
Clovis (CLVS) misses estimates in the third quarter for both earnings and sales and guides lower sales for only marketed drug, Rubraca in Q4. Shares decline.
Zacks.com highlights: Bristol-Myers Squibb, United Rentals, Capital One Financial and Harris
by Zacks Equity Research
Zacks.com highlights: Bristol-Myers Squibb, United Rentals, Capital One Financial and Harris
The Zacks Analyst Blog Highlights: ArcBest, Express, Arch Coal, Bristol-Myers Squibb and Methanex
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ArcBest, Express, Arch Coal, Bristol-Myers Squibb and Methanex
The Pharmaceuticals Industry Stock Outlook: A Steady Path Ahead
by Kinjel Shah
Pipeline success, cost cutting, share buybacks, product launches, increased M&A and collaboration activities are the factors that drives the large-cap pharma industry.
Exelixis (EXEL) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Exelixis' (EXEL) third-quarter results are expected to benefit from Cabometyx performance and other pipeline updates.
Is Halloween the Best Time to Invest? 5 Solid Buys
by Tirthankar Chakraborty
Halloween is around the corner and it marks the best stretch of growth for the stock market. The economy is also strong, which could extend the bull market.
5 Stocks With Solid Sales Growth Worth Buying Right Away
by Zacks Equity Research
Sales growth is an early indicator of a company's future earnings performance.
New Strong Buy Stocks for October 30th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
Can the Strong Economy Save the Stock Market?
by John Blank
The U.S. economy is the MOST important fundamental.
Bristol-Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Bristol-Myers Squibb (BMY) closed the most recent trading day at $49.73, moving -1.39% from the previous trading session.
The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers (Revised)
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers
Pharma Stock Roundup: MRK, BMY Q3 Earnings, Cancer Data Presentations at ESMO
by Zacks Equity Research
Merck (MRK) and Bristol-Myers (BMY) report mixed third-quarter results. Pharma bigwigs present cancer data at ESMO.
Bristol-Myers (BMY) Beats on Q3 Earnings, Raises EPS View
by Zacks Equity Research
Bristol-Myers (BMY) beats earnings estimates in the third quarter but misses sales expectation by a slight margin. Eliquis and Opdivo continue to record solid sales.
Why Bristol-Myers Squibb (BMY) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
Bristol-Myers Squibb (BMY) Q3 Earnings Beat Estimates
by Zacks Equity Research
Bristol-Myers (BMY) delivered earnings and revenue surprises of 19.78% and -0.48%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Drug Stocks' Earnings Due on Oct 25: MRK, BMY, GILD & CELG
by Zacks Equity Research
Four drug/biotech stocks are scheduled to release their third-quarter results on Oct 25. Let???s take a look at how these companies are poised ahead of their earnings release.
Bristol-Myers Declines, FDA Delays Review of Opdivo for NSCLC
by Zacks Equity Research
The FDA defers decision by three months regarding the sBLA of Bristol-Myers' (BMY) Opdivo in combination with Yervoy for the treatment of metastatic first-line NSCLC.
The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers
Intel (INTC) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Robust performance from data-centric businesses, acquisition synergies and new deal wins are likely to benefit Intel's (INTC) third-quarter results.
Earnings Keep Pouring In: Global Week Ahead
by John Blank
So far, almost 90% of the firms have beaten analysts' earnings expectations. About 70% have beaten revenue expectations. This week, 156 S&P 500 firms release earnings.